Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

INIBIDOR DE PARP NIRAPARIB + BEVA VERSUS NIRAPARIB ISOLADO AUMENTANDO INTERVALO LIVRE DE DOENÇA , PARA GRUPO BRCA MUTADO BENEFÍCIO DE 51% , COM PFS 14,4 MESES E BRCA WT BENEFÍCIO DE 78% COMPARADO AO CONTROLE COM PFS DE 11,3 MESES 














Comentários

Postar um comentário

Postagens mais visitadas deste blog

Imagem
 https://sabcs.onlineeventpro.freeman.com/posters/25581279/Efficacy-and-tolerability-of-neoadjuvant-Pertuzumab-Trastuzumab-and-weekly-Paclitaxel-in-Locally-advanced-Her-2-positive-Breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25582333/Phase-II-pilot-study-of-trastuzumab-biosimilar-herzuma-plus-gedatolisib-in-patients-with-HER-2-positive-metastatic-breast-cancer-who-progressed-after-2-or-more-HER-2-directed https://sabcs.onlineeventpro.freeman.com/posters/25581672/HER2CLIMB-02-A-randomized-double-blind-phase-3-study-of-tucatinib-or-placebo-with-T-DM1-for-unresectable-locally-advanced-or-metastatic-HER2-breast-cancer          
Leia mais